This page shows the latest cancer patients news and features for those working in and with pharma, biotech and healthcare.
The phase 2 Destiny-Breast01 study investigated trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients, who had already received two or more prior HER2-targeting therapies. ... Its HER2CLIMB trial evaluated the drug as an add-on
response in four of six patients whose cancer was resistant to Imbruvica and has exhausted all available therapies. ... The latter also had some new data at ASH from a phase 1b/2 dose-escalation trial, still ongoing, which showed evidence of stable
Around 22% of ovarian cancer patients carry a BRCA mutation (15% germline and 7% somatic), which must be identified via a companion diagnostic death. ... therapy for women with newly-diagnosed advanced ovarian cancer, regardless of their biomarker status
The demise of the drug in stroke means Evgen is now focused on its STEM breast cancer study of SFX-01, which generated encouraging preliminary results earlier this year. ... The open-label study suggested giving SFX-01 alongside these drugs improved
The FDA’s acceptance of our application for Opdivo plus Yervoy represents important progress for patients with liver cancer in the US, where hepatocellular carcinoma is the fastest rising cause of ... Despite recent advances, hepatocellular carcinoma
For example, NHS England has already committed to focusing on earlier diagnosis and increased personalised medicines for cancer and rare disease patients. ... It has also launched the Genomics Medicine Service, which aims to deliver routine clinical care
More from news
Approximately 0 fully matching, plus 1,025 partially matching documents found.
For example, skin cancer patients who carry a BRAF V600 mutation are more likely to respond to BRAF inhibitors like Roche’s Zelboraf (Vemurafenib) than people without such mutations. ... In June 2018, Bristol Myers-Squibb sought approval for Opdivo and
findings in up to half of cancer patients. ... Of equal importance is support for patients and families, especially in reaching a correct diagnosis as early as possible.
Last year, NHS England announced that it will focus on earlier diagnosis and more personalised medicines for cancer and rare disease patients, and it will further that goal by launching a ... The data has to be managed very carefully, with the benefits
Thus far, researchers have been unable to identify which cancer drug will work most effectively for specific patients, ie, precision medicine. ... A groundbreaking study in 2018 on patients with recurrent metastatic cancer showed that organoids are
lung cancer NSCLC patients with low PD-L1 expression (1%, also without EGFR or ALK mutations) – a group that was once thought unlikely to benefit from these drugs. ... April. Naturally Merck &Co isn’t confining itself to dominance in lung cancer.
More from intelligence
Approximately 0 fully matching, plus 53 partially matching documents found.
pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the potential to improve the outcome for cancer patients has never ... He is an active member of the American Society of Clinical
It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell
Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as its chief medical and scientific officer. ... class new treatments for cancer patients and to help transform the company into a world-class
We make medicines that help patients with cancer live longer and what a privilege it’s been to wake up each morning with that as my life’s work.”.
Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and ... targeted cancer therapies and treating patients.
More from appointments
Approximately 0 fully matching, plus 32 partially matching documents found.
half now, to three quarters of cancer patients by 2028. ... The Long-term Plan says that the NHS wants to use personalised and risk stratified screening and begin to test family members of cancer patients if they have an increased risk
Abiraterone. Zytiga. Janssen. Treatment of patients with metastatic castration-resistant prostate cancer. . ... Non-small cell lung cancer treatments, due to their still-evolving place in therapy:.
While science and technology are progressing rapidly, some stakeholders are still reeling from the seismic shift in the way patients are treated. ... As a result, the ‘zip code lottery’ and patients’ financial constraints are fundamental to cancer
The trial wasn’t designed for patients like Laura with the BRCA2 mutation, but the research suggested it would be a potent treatment for her type of cancer. ... Cancer patients require a lot of support, regardless of whether they are trying a novel
Here, the author and precision medicine advocate tells her story and explains what industry needs to remember when treating cancer patients with precision medicine. ... Patients feel awful physically and are trying to cope with the reality and emotions
More from PMHub
Approximately 1 fully matching, plus 64 partially matching documents found.
We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...